Oral tolerance in myasthenia gravis

Area of Science:

• Immunology
• Neuroimmunology
• Autoimmune Diseases

Background:

• Myasthenia gravis (MG) is an antibody-mediated autoimmune disease.
• The acetylcholine receptor (AChR) is a key autoantigen in MG.
• Oral antigen administration is a potential therapeutic strategy.

Purpose of the Study:

• To investigate the effects of oral autoantigen (AChR) administration on experimental autoimmune myasthenia gravis (EAMG).
• To understand the impact of antigen dose, purity, and feeding protocol on immune tolerance.
• To explore the potential for developing safer oral treatments for ongoing autoimmune disease.

Main Methods:

• Oral administration of AChR antigen before and after immunization in an EAMG model.
• Evaluation of clinical manifestations, antibody responses, and cellular responses (lymphocyte proliferation, IL-2 production).
• Comparison with tolerance induction to an unrelated antigen (OVA).

Main Results:

• Pre-immunization feeding of AChR prevented EAMG, inducing antigen-specific tolerance with delayed antibody response inhibition.
• Cellular responses to AChR were significantly inhibited.
• Oral AChR administration after immunization inhibited clinical EAMG but paradoxically enhanced AChR-antibody responses.
• Tolerance induction varied based on antigen nature and feeding regimen.

Conclusions:

• Oral antigen administration can modulate autoimmune responses in EAMG.
• The effectiveness of oral tolerance is antigen-specific and protocol-dependent.
• A less immunogenic AChR-based molecule may be necessary for treating active MG.